Illumina Ventures and AV8 Ventures returned for a series A round that will push the startup's liquid biopsy technology towards the clinical trial stage.
US-based biopsy test developer Delfi Diagnostics has secured $100m in a series A round featuring Illumina Ventures and AV8 Ventures, which invested on behalf of genomics technology provider Illumina and insurer Allianz respectively.
Healthcare investment firm OrbiMed led the round, which included Menlo Ventures, Samsara Biocapital, Windham Venture Partners, Foresite Capital, Northpond Ventures, Cowen Healthcare Investments, Rock Springs Capital and funds and accounts advised by T. Rowe Price.
Delfi is using machine learning technology and recent DNA research to develop…
